Founded in 1999, BGI is one of the world's leading life science and genomics organizations. BGI’s mission is to use genomics to benefit mankind and to be a leader in the era of life sciences. BGI follows a genomics development model of “research, production and application”. With businesses in more than 100 countries and regions around the world, BGI has established cooperation and partnerships with thousands of different organizations across multi-disciplinary research areas including medical health, resource conservation and judicial services. At the same time, BGI provides equipment, technical support and solutions for the needs of national economies and people's livelihoods, such as precision medicine and precision health. BGI is committed to applying its genetic and technological achievements to real world settings in order to realize the dream of trans-omics for a better life.

With advanced genetic reading, writing and storage, multi-disciplinary and new biological research system and abundant application cases, BGI has established extensive collaborations with domestic and international standardization organizations, industry-leading research institutions and enterprises, aiming at building the most influential standards and databases in the field of life science, and promoting the development of human health services and technology applications, based on “big platform”, “big data”, “big science”, “big industry” and “big livelihood project”.

BGI participates in more than a dozen industry standard organizations or industry alliances, and assumes more than a dozen important seats, serving as vice chairperson, director of China, president of the association, or expert committee in organizations such as ISO, ISBER, SZAS, and LTIA. At the same time, BGI actively submitted standard proposals. In 2020, more than 69 standard proposals were submitted, and more than 260 were submitted in total, making important contributions to promoting the development and implementation of the world's leading standards and escorting the development of the industry. A number of high-throughput genetic sequencing reference materials developed in cooperation with National Institutes for Food and Drug Control of China, National Institute of Metrology of China and other units are indispensable tools for metrological calibration in the industry and fill many industry gaps.

BGI not only participates in existing standards organizations, but also advocates and takes the lead in establishing new standards organizations in accordance with the development needs of emerging technologies to promote and regulate the development of new technologies. For example, in 2018 and 2020, BGI has led the establishment of the National Information Technology Standardization Committee Biometric Sub-Committee (SAC / TC28 / SC37) Genome Identification Working Group and the National Biochemistry Products and Testing Technology Standardization Committee (SAC / TC387 / WG1) Data and Database Working Group, and has organized several plenary meetings of the working group to promote the development and implementation of a number of national standards for genetic data and genetic data security.

In addition, as the first comprehensive standardization pilot for the gene industry in Guangdong Province, BGI successfully passed the acceptance in 2017. In 2019, BGI was rated as a Shenzhen R&D and standardization synchronous A-level demonstration enterprise. The national standardization pilot for genetic health services undertaken by BGI in 2020 passed the acceptance smoothly. The Guangdong Province High-tech Service (Gene Health) Standardization Demonstration Project that BGI applied in 2021 was also successfully approved.

By the end of May 2022, BGI has applied for 4,575 domestic and foreign patents, including 53 countries and regions such as China, Europe, the United States and Japan, and has obtained 1,715 patents in total.

华大成立于1999年，是全球领先的生命科学前沿机构。秉承“基因科技造福人类”的使命，怀抱“健康美丽，做生命时代的引领者”的愿景，华大以“产学研”一体化的发展模式引领基因组学的创新发展，通过遍布全球100多个国家和地区的分支机构，与产业链各方建立广泛的合作，将前沿的多组学科研成果应用于医学健康、资源保存、司法服务等领域。同时，为精准医疗、精准健康等关系国计民生的实际需求提供自主可控的先进设备、技术保障和解决方案。坚持走“自我实践、民生切入、科研拓展、产业放大、人才成长”的新型发展道路，做到五环联动、循序递进，切实推动基因科技成果转化，实现基因科技造福人类。

华大依托先进的存、读、写能力，多学科结合的新型生物科研体系和丰富的产业应用案例，以大平台、大数据、大科学、大产业、大民生为基础，在全球范围内，与国内外标准化组织及行业领先研究机构、企业建立了广泛的合作关系，携手构建生命科学领域最具影响力的标准和数据库，助推人类健康服务事业和科技应用领域的发展。

华大参与十几个行业标准组织或产业联盟，并承担十多个重要席位，在ISO、ISBER、SZAS、LTIA等组织担任副主席、中国区主席、协会会长或专家委员。同时，华大积极提交标准提案，2020年提交标准提案超过69篇，累计提交260多篇，为促进全球领先标准的研制和实施，护航产业发展做出重要贡献。与中国食品药品检定研究院、中国计量科学研究院等单位合作开发的多个高通量基因测序标准物质，是行业内计量校准必不可少的工具，填补了多项行业空白。

华大不仅参与已有的标准组织，还根据新兴技术的发展需要，倡议并牵头建立新的标准组织，以推动和规范新技术的发展。例如，华大在2018年和2020年先后牵头成立了全国信息技术标准化委员会生物特征识别分技术委员会（SAC/TC28/SC37）基因组识别工作组和全国生化检测标准化技术委员会（SAC/TC387/WG1）数据及数据库工作组，组织了数次工作组全体会议，推动多项基因数据及基因数据安全国家标准的研制与实施。

除此之外，华大作为广东省首个基因产业综合标准化试点于2017年顺利通过验收，2019年被评为深圳市研发与标准化同步A级示范企业，2020年承担的基因健康服务国家级标准化试点顺利通过验收，2021年申请的广东省高新技术服务（基因健康）标准化示范点项目也顺利获批。

截止2022年5月，华大累计申请国内外专利4575件，专利申请的国家包括中国、欧洲、美国、日本等53个国家和地区，累计已获得专利权1715件。